Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
International Prognostic Index
78%
Elderly Patient
32%
Malignant Neoplasm
29%
Overall Survival
25%
Cohort Analysis
17%
Peripheral T-Cell Lymphoma
16%
Psychoactive Drug
16%
Cohort Effect
16%
Drug Use
16%
Large-Cell Lymphoma
16%
Hematological Cancer
16%
Non-Hodgkin Lymphoma
16%
Mental Health
16%
CHOP
16%
Patient with Non-Hodgkins Lymphoma
16%
Beta 2 Microglobulin
16%
Clinical Trial
15%
Radiation Therapy
12%
Salvage Therapy
10%
Cumulative Incidence
10%
Diseases
10%
High Risk Population
9%
B Symptoms
9%
Rituximab
9%
Medical Record
8%
Oral Drug Administration
5%
Targeted Therapy
5%
Electrocorticography
5%
Arm
5%
Lactate Dehydrogenase
5%
Supportive Care
5%
Monoclonal Antibody
5%
Anthracycline
5%
Adrenal Gland
5%
Testes
5%
Proportional Hazards Model
5%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
80%
Malignant Neoplasm
47%
Overall Survival
20%
Cohort Study
17%
Nonhodgkin Lymphoma
16%
Large Cell Lymphoma
16%
Psychotropic Agent
16%
Beta 2 Microglobulin
16%
Chemotherapy
10%
Clinical Trial
10%
Rituximab
7%
Disease
7%
Monoclonal Antibody
5%
Anthracycline
5%
Lactate Dehydrogenase
5%
Survival Rate
5%
Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
32%
International Prognostic Index
26%
National Comprehensive Cancer Network
24%
Lymphoma Patients
18%
Prognostic Marker
16%
β2-microglobulin (β2-MG)
16%
Trial Eligibility
16%
Data-driven Analysis
16%
Prognostic Score
16%
Clinical Nomogram
16%
Last Line
5%
Novel Targeted Therapy
5%